Key facts
- Notable investors include Tech Incubator Program for Startup, HG Initiative.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Excellamol
- ·The full record, as it builds
Funding rounds
No funding rounds for Excellamol are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Excellamol
Developer of polypeptide-drug conjugates designed for oncology applications. The company's platform integrates cancer cell receptor-binding sequences, temperature-sensitive intrinsically disordered polypeptides, and potent antineoplastic agents, enabling the oncology market to target tumor microenvironments with high selectivity and prolonged retention, enabling researchers to enhance treatment efficacy and minimize side effects.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2020
- Website
- excellamol.com/
- Ownership
- Privately Held (backing)
Excellamol doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Excellamol shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Excellamol in its N-PORT filings yet. We sweep new filings monthly.